Last reviewed 2026-04-19 · How we verify

seromycin

At a glance

Approved indications

• Acute tuberculosis
• Bacterial urinary infection
• Escherichia coli urinary tract infection
• Pulmonary tuberculosis

Common side effects

No common side effects on file.

Key clinical trials

• Lower Limb Function After Spinal Cord Injury (Phase 4)
• D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder (Phase 2)
• D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression: A Multi-Site, Randomised, Placebo-Controlled Trial (COGENT) (Phase 2)
• The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls. (N/A)
• Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes (Phase 3)
• Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder (Phase 4)
• A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression (Phase 2)
• Developing Memory Reconsolidation Blockers as Novel PTSD Treatments (Phase 4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• seromycin CI brief — competitive landscape report
• seromycin updates RSS · CI watch RSS
• Massachusetts General Hospital portfolio CI